Účtovná hodnota akcie spoločnosti Inhibrx
Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Inhibrx?
Hodnota metriky Účtovná hodnota akcie spoločnosti Inhibrx, Inc. je 0.51
Aká je definícia metriky Účtovná hodnota akcie?
Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účtovná hodnota akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Inhibrx
Čomu sa venuje spoločnosť Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Inhibrx
- Hodnota metriky Účtovná hodnota akcie spoločnosti Chong Hing Bank je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Perfectech International je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Hancock Jaffe Laboratories Inc je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Roxgold je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Witbe SA je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Planet 13 je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Inhibrx je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Perseus Mining je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Fission Uranium je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Coronado Global Resources je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Stereotaxis je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Planet Green Corp je 0.51
- Hodnota metriky Účtovná hodnota akcie spoločnosti Qianhai Health je 0.51